Reviva Pharmaceuticals Holdings, Inc. Derivative Liability, Current
Reviva Pharmaceuticals Holdings, Inc. (RVPH) had Derivative Liability, Current of $1.96 million as of 2020-12-31, per its 10-K/A filed 2021-05-07.
Discontinued › Balance Sheet › Liabilities
us-gaap:DerivativeLiabilitiesCurrent · last filed 2021-05-07
- 2020-12-31: Derivative Liability, Current $1.96M.
- 2019-12-31: Derivative Liability, Current $101.53K.
| Period end | Derivative Liability, Current |
|---|---|
| 2020-12-31 | $1.96M 10-K/A · filed 2021-05-07 |
| 2019-12-31 | $101.53K 10-K/A · filed 2021-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |